Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Net Margin (2016 - 2026)

Amphastar Pharmaceuticals has reported Net Margin over the past 13 years, most recently at 31.9% for Q4 2025.

  • For Q4 2025, Net Margin rose 865.0% year-over-year to 31.9%; the TTM value through Dec 2025 reached 18.35%, down 426.0%, while the annual FY2025 figure was 18.35%, 426.0% down from the prior year.
  • Net Margin for Q4 2025 was 31.9% at Amphastar Pharmaceuticals, up from 9.04% in the prior quarter.
  • Over five years, Net Margin peaked at 31.9% in Q4 2025 and troughed at 81.55% in Q4 2023.
  • A 5-year average of 9.31% and a median of 18.64% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -8862bps in 2022 and later surged 10481bps in 2024.
  • Year by year, Net Margin stood at 19.57% in 2021, then tumbled by -453bps to 69.05% in 2022, then decreased by -18bps to 81.55% in 2023, then surged by 129bps to 23.26% in 2024, then surged by 37bps to 31.9% in 2025.
  • Business Quant data shows Net Margin for AMPH at 31.9% in Q4 2025, 9.04% in Q3 2025, and 17.79% in Q2 2025.